January 2024 | Jeroen Dauw, Kristina Charaya, Malgorzata Lelonek, Isabel Zegri-Reiriz, Samer Nasr, Cynthia P. Paredes-Paucar, Attila Borbély, Fatih Erdal, Riad Benkouar, Marta Cobo-Marcos, Gonzalo Barge-Caballero, Varghese George, Cornelia Zara, Noël T. Ross, Diane Barker, Anoop Lekhakul, Simone Frea, Azmee M. Ghazi, Dorit Knappe, Nawal Doghmi, Milka Klincheva, Inês Fialho, Virginia Bovolo, Hajo Findeisen, Imad A. Alhaddad, Alessandro Galluzzo, Rafael de la Espriella, Ramzi Tabbalat, Óscar Miró, Jagdeep S. Singh, Petra Nijst, Matthias Dupont, Pieter Martens, Wilfried Mullens
The ENACT-HF study (Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure) investigated the feasibility and efficacy of a standardized natriuresis-guided diuretic protocol in patients with acute heart failure (AHF) and signs of volume overload. The study was an international, multicenter, open-label, pragmatic, 2-phase trial comparing the current standard of care with a standardized diuretic protocol that included urinary sodium to guide therapy. The primary endpoint was natriuresis after 1 day, and secondary endpoints included cumulative natriuresis and diuresis after 2 days, length of stay, and in-hospital mortality. Four hundred one patients from 29 centers in 18 countries were included. The protocol arm showed significantly higher natriuresis and diuresis after 1 and 2 days compared to the standard of care arm. The protocol arm also had a shorter length of stay, but in-hospital mortality was low and did not differ between the two arms. The study concluded that a standardized natriuresis-guided diuretic protocol is feasible, safe, and effective in improving diuretic response and reducing length of stay in patients with acute heart failure.The ENACT-HF study (Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure) investigated the feasibility and efficacy of a standardized natriuresis-guided diuretic protocol in patients with acute heart failure (AHF) and signs of volume overload. The study was an international, multicenter, open-label, pragmatic, 2-phase trial comparing the current standard of care with a standardized diuretic protocol that included urinary sodium to guide therapy. The primary endpoint was natriuresis after 1 day, and secondary endpoints included cumulative natriuresis and diuresis after 2 days, length of stay, and in-hospital mortality. Four hundred one patients from 29 centers in 18 countries were included. The protocol arm showed significantly higher natriuresis and diuresis after 1 and 2 days compared to the standard of care arm. The protocol arm also had a shorter length of stay, but in-hospital mortality was low and did not differ between the two arms. The study concluded that a standardized natriuresis-guided diuretic protocol is feasible, safe, and effective in improving diuretic response and reducing length of stay in patients with acute heart failure.